International Journal of Nanomedicine (Oct 2020)
Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer
Abstract
Ruben AG van Eerden,1 Ron HJ Mathijssen,1 Stijn LW Koolen1,2 1Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 2Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, the NetherlandsCorrespondence: Ruben AG van EerdenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, PO Box 2040, Rotterdam 3000 CA, the NetherlandsTel +31 10 7039640Email [email protected]: Conventional taxanes are used as cornerstone of the chemotherapeutical treatment for a variety of malignancies. Nevertheless, a large proportion of patients do not benefit from their treatment while they do suffer from severe adverse events related to the solvent or to the active compound. Cremophor EL and polysorbate 80 free formulations, conjugates, oral formulations and different types of drug delivery systems are some examples of the several attempts to improve the treatment with taxanes. In this review article, we discuss recent clinical developments of nanomediated drug delivery systems of taxanes for the treatment of cancer. Targeting mechanisms of drug delivery systems and characteristics of the most commonly used taxane-containing drug delivery systems in the clinical setting will be discussed in this review.Keywords: nanomedicine, nanoparticle, drug delivery systems, taxane, cancer
